Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | CIT | O14578 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246519 | 0.86 | LTA4H (0.46) | LTA4HLNPEPERAP2 | |
| SCHEMBL4950370 | 0.82 | TAAR1 (0.59) | LTA4HROCK2ROCK1LNPEPERAP2 | |
| SCHEMBL15143051 | 0.79 | LTA4H (0.56) | LTA4HROCK2ROCK1LNPEPERAP2 | |
| SCHEMBL27744399 | 0.79 | AAK1 (0.61) | LTA4HROCK2ROCK1CITTAAR1 | |
| SCHEMBL4533616 | 0.79 | AAK1 (0.61) | LTA4HROCK2ROCK1CITTAAR1 | |
| SCHEMBL5184757 | 0.78 | ROCK1 (0.45) | ROCK2ROCK1 | |
| SCHEMBL17394729 | 0.74 | ROCK2 (0.70) | ROCK2ROCK1 | |
| SCHEMBL16006049 | 0.74 | ROCK2 (0.70) | ROCK2ROCK1 | |
| SCHEMBL1245420 | 0.74 | RAB9A (0.56) | ROCK2ROCK1 | |
| SCHEMBL4950599 | 0.74 | SMN1; SMN2 (0.62) | LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | REMPEX PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | LTA4H 1946/4885ROCK2 2234/4885ROCK1 2365/4885 |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | ABCB11, ABCB1, ABCC1 | LTA4H 1209/4885ROCK2 1383/4885ROCK1 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.